newsfilter
← Latest News
GlobeNewswire·

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

IXHL
  • Incannex Healthcare Inc. (NASDAQ: IXHL) won the "Best New Technology Solution for Drug Development" award at the 10th annual MedTech Breakthrough Awards.
  • The award recognizes the company's lead candidate, IHL-42X, an oral fixed-dose combination therapy for obstructive sleep apnea (OSA).
  • IHL-42X combines dronabinol and acetazolamide to target ventilatory control instability and upper airway dysfunction.
  • Phase 2 RePOSA clinical trial results showed statistically significant reductions in apnea-hypopnea index (AHI) alongside improvements in oxygenation, sleep quality, and fatigue.
  • CEO Joel Latham stated the award validates progress toward a first-in-class oral therapy that could redefine the OSA treatment paradigm.
  • The MedTech Breakthrough Awards program received thousands of nominations from over 20 countries.
  • Incannex is advancing IHL-42X through late-stage development while pursuing strategic opportunities to expand clinical potential.
  • The company's pipeline includes IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder.
  • Forward-looking statements in the release include risks regarding cash sufficiency and potential differences between projections and actual results.